Obstetrics and Gynecology · 1995 · 65 citations · 16 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis PharmacologyCytotoxic ChemotherapyMalignant NeoplasmsOvarian CancerOvarian NeoplasiaCancer Cell ApoptosisCell Death In CancerChemotherapy-induced ApoptosisOvarian ApoptosisOvarian Cancer ChemotherapyP53 AbnormalityP53 MutationPrimary Ovarian Carcinoma
OBJECTIVE: To determine whether chemotherapy drugs elicit programmed cell death (apoptosis) in ovarian cancer cells. METHODS: Monolayers of immortalized ovarian cancer cell lines and primary ovarian cancer cells obtained from ascites were grown in the presence of cisplatin, 4-hydroxyperoxy-cyclophosphamide (the active metabolite of cyclophosphamide) or paclitaxel. Next, DNA was extracted from the cells and subjected to electrophoresis to determine if DNA laddering characteristic of apoptosis was present. RESULTS: In three of six immortalized cell lines (OVCA 420, 429, and 433), apoptosis was not seen in response to any of the three drugs. In contrast, in OVCAR-3 and OVCA 432, DNA laddering consistent with apoptosis was observed in response to all three drugs. In the DOV 13 cell line, apoptosis was seen only with 4-hydroxyperoxycyclophosphamide. Among three primary ovarian cancers, cisplatin elicited apoptosis in one case. Both cell lines with mutant p53 genes (OVCAR-3 and OVCA 432) underwent apoptosis in response to all three drugs, whereas among three cell lines known to have normal p53 genes, one underwent apoptosis in response to 4-hydroxyperoxycyclophosphamide and two were unaffected. CONCLUSION: Ovarian cancer cell death in response to commonly used chemotherapeutic drugs involves the induction of a genetically programmed sequence of events (apoptosis) rather than simply necrosis.
16
INVOLVEMENT OF APOPTOSIS IN OVARIAN FOLLICULAR ATRESIA AND POSTOVULATORY REGRESSION
Jonathan L. Tilly, K. I. Kowalski, A. L. Johnson et al. · Endocrinology · 1991 · 670 citations
Medicine, Cell Biology, Gynecology +17
Overexpression and mutation of p53 in epithelial ovarian cancer.
Jeffrey R. Marks, A M Davidoff, B. J. Kerns et al. · PubMed · 1991 · 471 citations · Full text
Taxol: Mechanisms of Action and Resistancea
Susan Band Horwitz, Leonard Lothstein, James J. Manfredi et al. · Annals of the New York Academy of Sciences · 1986 · 417 citations